ing 9 randomized, double-blind, placebo-controlled trials studying the effi cacy of probiotics in this setting. In these trials, 3 different probiotics ( S. boulardii, Lactobacillus spp. and Enterococcus faecium ) were used. The odds ratio for diarrhea to occur was similar for all species. The combined odds ratio was 0.37 (95% confi dence interval 0.26-0.53; p ! 0.01) in favor of active treatment over placebo. This analysis has been criticized because of its inconsistent defi nition of diarrhea and that more than half of the studies did not analyze the data on an intention-to-treat basis. The second meta-analysis by Cremonini et al. [4] included only 7 studies with more consistent defi nitions of outcome. The results were similar. The combined relative risk was 0.39 (95% confi dence interval 0.27-0.57). According to these two meta-analyses the results infer that the use of Lactobacillus spp. and S. boulardii in the prevention of antibiotic-associated diarrhea are beneficial.
Antibiotic-associated diarrhea is a frequent side effect of broad-spectrum antibiotics. The clinical presentation of diarrhea reaches from mild to fulminant pseudomembranous Clostridium diffi cile toxin-induced colitis. The frequency of antibiotic-associated diarrhea can affect as many as 25% of patients. In the last decade, there has been an increase of antibiotic-associated diarrhea of 500%. In up to 80%, the cause of diarrhea is not clear [1] .
One of the mechanisms for the development of antibiotic-associated side effects seems to be related to an alteration in the intestinal fl ora. The intestinal fl ora protects the individual against enteral pathogens by multiple mechanisms: (a) production of bacteriocins; (b) competitive inhibition of binding to the mucosa; (c) enhancing synthesis of mucus, and (d) secretion of secretory IgA [2] .
Probiotics (life-viable, non-pathogen microbial organisms) have been shown to have immune modulatory properties and to enhance the mucosal barrier. In fact, probiotics have anti-bacterial, anti-viral and anti-infl ammatory properties and restore the intestinal fl ora balance; they were fi rst used for the treatment or prevention of antibiotic-associated diarrhea. Several probiotics, such as treatment with probiotics. There were only 2 homogeneous studies looking at Helicobacter pylori eradication with small numbers of patients included; the same dose and duration of probiotics and the same antibiotics were administered. The reported trials in this systematic review were published in the period ranging from 1990 to 2002 with different methodological qualities (Jadad score between1 and 5). With these limits in mind, the authors could confi rm the fi ndings of the previously reported meta-analysis. In 4 of 6 trials a signifi cant reduction in the risk of antibiotic-associated diarrhea was noted with the co-administration of L. rhamnosus GG. Unfortunately, the study with the largest sample size undertaken in hospitalized patients was negative. One potential explanation for these results could be that these patients were sicker than in the other studies, which included only ambulatory patients.
In the evolutionary battle against infectious gastrointestinal disease, probiotics seem to be useful agents to prevent or treat these diseases. Very interesting is the prevention of antibiotic-associated diarrhea. Several other publications (not included in the previous meta-analysis or in the systematic review of Hawrelak et al. [5] ) have recently been published. In a double-blind, placebo-controlled study involving 150 elderly patients with an antibiotic regimen, a probiotic mixture of Lactobacillus and Bifi dobacterium showed a signifi cant reduction in C. diffi cile toxin in the probiotic group compared to the placebo group (46 vs. 78%) [5] . With respect to diarrhea, the incidence of samples positive for C. diffi cile -associated toxin was 2.9% in the probiotic group compared to 7.25% in the placebo group [6] . Erdeve et al. [7] tested the effect of probiotics in children receiving an antibiotic treatment. 462 children aged 1-5 years receiving sulbactamampicillin or azithromycin were randomized to the treatment with S. boulardii or antibiotics alone. Antibiotic-associated diarrhea was found in 19% receiving an antibiotic treatment alone and in 6% with the additional probiotic treatment. Finally, a recently published study performed with Bacillus clausii reduced the incidence of nausea, diarrhea and epigastric pain associated with a triple anti-H. pylori therapy as compared to placebo [8] .
One major limitation of all published results is the inhomogeneous and variable defi nition of diarrhea. In the future, to overcome these problems, it is absolutely mandatory to perform trials with adequate power using the same probiotics with the same doses and duration using a standard and uniform defi nition of diarrhea. Such trials should demonstrate that a co-treatment with probiotics will defi nitely reduce antibiotic-associated side effects and reduce health care costs.
